Skip to main content

‘Outstanding’ trust appoints new CEO

Published on: 2 Aug 2022
Category:

A specialist trust has promoted its chief operating officer to be its new chief executive.

Eilish Midlane, Royal Papworth Hospital Foundation Trust’s chief operating officer, will replace Stephen Posey. Mr Posey is taking up the CEO role at University Hospitals of Derby and Burton FT in September.

Ms Midlane joined Royal Papworth as COO in 2017. She helped oversee the trust’s logistically complex move from its former Everard site just outside Cambridge to its new £200m hospital on the Cambridge Biomedical Campus in 2019.

The trust said she would formerly take on the CEO role later this month. Meanwhile, chief finance officer Tim Glenn will take on the deputy chief executive position as part of his remit following Ms Midlane’s promotion.

Royal Papworth, one of the world’s leading cardiothoracic hospitals and the UK’s main heart and lung transplant centre, has performed well in recent years.

During Mr Posey’s time at Royal Papworth, the trust was the first in the country to receive an “outstanding” rating across all inspection domains from the Care Quality Commission in October 2019. Mr Posey was also named one of HSJ’s top 50 chief executives for 2022.

Ms Midlane, formerly divisional director of clinical support services at East and North Hertfordshire Trust, said: “It is a huge privilege to be given the opportunity to take up the role of chief executive at an organisation with a regional, national, and international reputation for excellence and innovation.

Trust chair John Wallwork said: “Eilish brings a wealth of strategic experience at an executive leadership level.

“As well as a detailed knowledge of the fabric of our organisation and our ambitions, Eilish provides the resilience to help the trust meet the challenges and changes facing the health service.

“Eilish holds significant NHS expertise in service improvement and delivery, and I am delighted that she is taking up this position as we continue on our journey to deliver tomorrow’s treatments to today’s patients.”